Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort-Reference-Cited by-同舟云学术

Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort

Published:2023-07-24 Issue:7 Volume:13 Page:1120
ISSN:2076-3425
Container-title:Brain Sciences
language:en
Short-container-title:Brain Sciences

Author:

Vancappel Alexis¹²³^ORCID,Dansou Yecodji¹,Godin Ophelia¹⁴,Haffen Emmanuel¹⁵^ORCID,Yrondi Antoine¹⁶^ORCID,Stephan Florian¹⁷,Richieri Raphaelle Marie¹⁸,Molière Fanny¹⁹,Holtzmann Jérôme¹¹⁰,Horn Mathilde¹,Allauze Etienne¹,Genty Jean Baptiste¹,Bouvard Alex¹¹¹¹²,Dorey Jean-Michel¹,Hennion Vincent¹¹³,Camus Vincent¹²,Fond Guillaume¹¹⁴,Peran Barbara¹⁷,Walter Michel¹⁷,Anguill Loic¹⁶,Scotto D’apolina Charlotte¹⁶,Vilà Estelle¹¹¹¹²,Fredembach Benjamin¹¹⁰,Petrucci Jean¹^ORCID,Rey Romain¹,Nguon Anne Sophie¹¹⁰,Etain Bruno¹¹³^ORCID,Carminati Mathilde¹¹³,Courtet Philippe¹⁹,Vaiva Guillaume¹¹⁵,Llorca Pierre Michel¹^ORCID,Leboyer Marion¹^ORCID,Aouizerate Bruno¹¹¹¹²^ORCID,Bennabi Djamila¹⁵,El Hage Wissam¹²^ORCID

Affiliation:

1. Fondation FondaMental, 94000 Créteil, France

2. CHRU de Tours, UMR 1253, iBrain, Université de Tours, Inserm, 37000 Tours, France

3. EE 1901 Qualipsy, Université de Tours, 37000 Tours, France

4. INSERM U955, Équipe de Psychiatrie Translationnelle, Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, 94000 Créteil, France

5. Department of Clinical Psychiatry, CIC-1431 INSERM, CHU de Besançon, UR481 Neurosciences and Cognition, University of Franche-Comté, 25000 Besançon, France

6. Service de Psychiatrie et de Psychologie Médicale de l’adulte, CHU de Toulouse, Hôpital Purpan, Université Paul Sabatier Toulouse 3, 31062 Toulouse, France

7. Service Hospitalo-Universitaire de Psychiatrie Générale et de Réhabilitation Psycho Sociale, 29200 Brest, France

8. Equipe Imothep, Institut Fresnel, UMR 7249, Aix-Marseille Université, CNRS, Ecole Centrale Marseille, 13284 Marseille, France

9. Department of Emergency Psychiatry and Post Acute Care, Hôpital Lapeyronie, CHU Montpellier, 34000 Montpellier, France

10. Service Hospitalo-Universitaire de Psychiatrie, CHU Grenoble Alpes, University Grenoble Alpes, 38400 Grenoble, France

11. Centre de Référence Régional des Pathologies Anxieuses et de la Dépression, Centre Expert Dépression Résistante, Pôle de Psychiatrie Générale et Universitaire, CH Charles Perrens, 33076 Bordeaux, France

12. Laboratoire Nutrition et Neurobiologie Intégrée (UMR INRAE 1286), Université de Bordeaux, 33076 Bordeaux, France

13. INSERM UMR-S 1144 Optimisation Thérapeutique en Neurospsychopharmacologie, Département de Psychiatrie et de Médecine Addictologique, OTeN, Hôpitaux Lariboisière-Fernand Widal, GHU APHP Nord_Université Paris Cité, 75006 Paris, France

14. Clinical Research Unit, Academic Hospitals of Marseille (APHM), School of Medicine–La Timone Medical Campus, EA 3279, Department of Epidemiology and Health Economics, Aix-Marseille University, 13284 Marseille, France

15. Inserm-U1172–LilNCog–Lille Neuroscience & Cognition, Centre National de Ressources & Résilience pour les Psychotraumatismes (Cn2r Lille Paris), Université de Lille (CHU Lille), 59000 Lille, France

Abstract

Previous studies set out profound cognitive impairments in subjects with treatment-resistant depression (TRD). However, little is known about the course of such alterations depending on levels of improvement in those patients followed longitudinally. The main objective of this study was to describe the course of cognitive impairments in responder versus non-responder TRD patients at one-year follow-up. The second aim was to evaluate the predictive aspect of cognitive impairments to treatment resistance in patients suffering from TRD. We included 131 patients from a longitudinal cohort (FACE-DR) of the French Network of Expert TRD Centers. They undertook comprehensive sociodemographic, clinical, global functioning, and neuropsychological testing (TMT, Baddeley task, verbal fluencies, WAIS-4 subtests, D2 and RLRI-16) at baseline (V0) and one-year follow-up (V1). Most patients (n = 83; 63.36%) did not respond (47 women, 49.47 ± 12.64 years old), while one-third of patients responded (n = 48, 30 women, 54.06 ± 12.03 years old). We compared the cognitive performances of participants to average theoretical performances in the general population. In addition, we compared the cognitive performances of patients between V1 and V0 and responder versus non-responder patients at V1. We observed cognitive impairments during the episode and after a therapeutic response. Overall, each of them tended to show an increase in their cognitive scores. Improvement was more prominent in responders at V1 compared to their non-responder counterparts. They experienced a more marked improvement in code, digit span, arithmetic, similarities, and D2 tasks. Patients suffering from TRD have significant cognitive impairments that persist but alleviate after therapeutic response. Cognitive remediation should be proposed after therapeutic response to improve efficiency and increase the daily functioning.

Publisher

MDPI AG

Subject

General Neuroscience

Link

https://www.mdpi.com/2076-3425/13/7/1120/pdf

Reference42 articles.

1. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.]. Available online: https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596.

2. The economic and social burden of depression;Sartorius;J. Clin. Psychiatry,2001

3. de Santé, H.A. (2017, April 10). Affections Psychiatriques de Longue durée Troubles Dépressifs Récurrents ou Persistants de l’Adulte. Available online: http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-04/gm_ald23_troubles_depressifs_webavril2009.pdf.

4. Inserm (2021, February 15). Dépression. Inserm—La Science Pour la Santé. Available online: https://www.inserm.fr/information-en-sante/dossiers-information/depression.

5. Morvan, Y., Prieto, A., Briffault, X., Blanchet, A., Dardennes, R., Rouillon, F., and Lamboy, B. (2007). La dépression en France: Prévalence, facteurs associés et consommation de soins. Baromètre Santé, 459–485. Available online: https://www.researchgate.net/publication/50298912_La_depression_en_France_Prevalence_facteurs_associes_et_consommation_de_soins.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression;Psychopharmacology;2024-07-04